| Title |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
|
|---|---|
| Published in |
Supportive Care in Cancer, January 2013
|
| DOI | 10.1007/s00520-012-1710-6 |
| Pubmed ID | |
| Authors |
Rudolph M. Navari, Cindy K. Nagy, Sarah E. Gray |
| Abstract |
Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an effective rescue medication for patients who develop breakthrough CINV despite having received guideline-directed CINV prophylaxis. |
X Demographics
The data shown below were collected from the profiles of 78 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 19 | 24% |
| United States | 6 | 8% |
| Australia | 2 | 3% |
| United Kingdom | 1 | 1% |
| China | 1 | 1% |
| Venezuela, Bolivarian Republic of | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 47 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 67 | 86% |
| Practitioners (doctors, other healthcare professionals) | 6 | 8% |
| Scientists | 4 | 5% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 141 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 139 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 14% |
| Other | 17 | 12% |
| Student > Doctoral Student | 17 | 12% |
| Student > Bachelor | 16 | 11% |
| Student > Ph. D. Student | 12 | 9% |
| Other | 29 | 21% |
| Unknown | 30 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 32 | 23% |
| Agricultural and Biological Sciences | 7 | 5% |
| Nursing and Health Professions | 5 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Other | 4 | 3% |
| Unknown | 34 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 75. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2023.
All research outputs
#578,979
of 25,718,113 outputs
Outputs from Supportive Care in Cancer
#28
of 5,115 outputs
Outputs of similar age
#4,132
of 292,389 outputs
Outputs of similar age from Supportive Care in Cancer
#1
of 40 outputs
Altmetric has tracked 25,718,113 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,115 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,389 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.